Islet antigen–peptide–major histocompatibility complex (Islet-pMHC)

The islet antigen–peptide–major histocompatibility complex (pMHC) is a central molecular assembly in the immunopathogenesis of Type 1 Diabetes (T1D). It consists of a peptide fragment derived from pancreatic islet autoantigens—such as insulin, glutamic acid decarboxylase 65 (GAD65), or zinc transporter 8 (ZnT8)—presented within the binding groove of a Human Leukocyte Antigen (HLA) molecule on the surface of antigen-presenting cells or beta cells (6.1.1, 6.2.1). This complex serves as the primary ligand for T-cell receptors (TCRs), and its recognition by autoreactive CD4+ and CD8+ T cells triggers the selective destruction of insulin-producing beta cells (6.1.3, 6.5.1). Therapeutic strategies targeting this complex aim to restore immune tolerance by either blocking the interaction with pathogenic T cells or by using soluble or nanoparticle-bound pMHCs (e.g., Navacims) to induce regulatory T-cell populations (6.3.1, 6.4.1). While antigen-specific therapies like GAD-alum and proinsulin peptides have been explored in clinical trials, the field is advancing toward more sophisticated modalities like TCR-like antibodies and CAR-Treg cells to achieve precise immunomodulation without the risks of systemic immunosuppression (6.4.2, 6.5.2).

Other names

Islet antigen–HLA peptide–MHC complexIslet-pMHC complexTrimolecular complexIslet autoantigen-MHC complexInsulin-HLA complexGAD65-HLA complexProinsulin-MHC complex

Induction of antigen-specific immune tolerance, activation of regulatory T cells (Tregs), and blocking of pathogenic T-cell receptor (TCR) recognition to prevent beta-cell destruction.